Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Randomised, 2-Arm Parallel Group, Multicentre, 8-Week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults.

Next Previous
X
Search
Trial Profile

Open-Label, Randomised, 2-Arm Parallel Group, Multicentre, 8-Week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms CAESAR
  • Sponsors AstraZeneca

    • Most Recent Events

    • 08 Aug 2011 Results published in Clinical Therapeutics.
    • 01 May 2010 Results presented at 25th Annual Scientific Meeting of the American Society of Hypertension.
    • 01 May 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top